Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

Inclusion Criteria: * Healthy men and women 18 to 60 years of age * Women of childbearing potential must have a negative urine pregnancy test within 3 days of study enrollment and must agree to use a highly effective form of contraception * Subjects must be in good health as determined by the Investigator based on medical history, ECG, physical examination and safety laboratory test * Ability to provide written informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study Exclusion Criteria: * Subjects with a known hypersensitivity to the investigational drug * Subjects who are pregnant or lactating * Participation in any investigational drug or device study and receipt of any investigational drug or device within the immediate 30 days prior to the start of this study * Concurrent or recent use of analgesics, steroids, allergy medications, H2 blockers within 48 hours of the start of the study * Subjects with a prior knee injury or surgery within the last 5 years * Subjects with an active infection or with a fever ≥ 38°C within 3 days of the start of the study * Subjects with a history of, or known to be positive for, HIV, hepatitis B or C * Subjects with uncontrolled hypertension as defined by systolic blood pressure (SBP) \> 150 mm/Hg, diastolic blood pressure (DBP) \> 100 mm/Hg * Subjects with a wound or skin irritation or any skin condition, e.g., psoriasis in the treatment area * Subjects who are taking prescription medications with the exception of oral or systemic contraceptives * Subjects who have systemic diseases * Subjects who have a history of anaphylactic reactions to any systemic or topical compounds